nearly four years holding this stock my best investment.i bought MPEL, at 3 1/2 so it is very close to SNTS, so,what is the future for this two stocks? i think, at least concerning about ,snts,better ask to KITYY,she is the one that has the better knowledge about SNTS .ILL' BE GOING TO EUROP, for a few months so GLTA.
I like SNTS prospects going forward and think we will be in the $20's soon. If Uceris is selling well as some have indicated, this should be an easy goal to meet. We also have the Ruconest catalyst for more attention from the investment community and a potential future growth driver. SNTS will potentially look at additional indications for Ruconest. Revs and earnings are key near term and we have momentum with resuming Zegerid sales and hopefully with nice Rx #'s for Uceris. With good revs and cash generation SNTS can bring in additional late stage or marketed products to add even more sales. Par may owe SNTS a nice tab (bonus). All of these things are positives and management knows what they are doing, so I am riding this one hopefully to the mid-$20's by year end or even $30. Traders may not see it this way; but I am a long term investor in this one. As always, do your DD and make the correct decision for your situation and comfort. Blessings to all SNTS longs.
What kind of earnings would we need to see to justify that kind of valuation (30pps)? At 66 the P/E seems very high to me already. But as I've said before, still figuring this stuff out. Maybe that kind of P/E is typical for a biopharm growth stock?
A new 52 week high. SNTS keeps going in the right direction. Where will she be this summer? Where will she be by the end of this year? IMO $30 by the end of the year is very conservative. What do you think wise Kitty?